Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiome changes after initiation of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis
NL-OMON54939Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in bacterial diversity after start of elexacaftor/tezacaftor/ivacaftor, Changes in respiratory microbiome composition and function and 2 more. Started Oct 2019; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON54939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54939.